Clinical trials: Neoadjuvant Treatment
Breast Cancer
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
More than three quarter of patients with breast cancer are treated by hormone pills called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone production.
- Trial name
- NCT02095184
- Testing
- Anastrozole, Letrozole
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy
1. Evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy and compare results to co-temporal volume change on grayscale ultrasound and post-treatment mammography findings…
- Trial name
- NCT01817374
- Testing
- 2D US grayscale plus quantitative VCEUS
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Non-Small-Cell Lung Cancer
Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer
To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.
- Trial name
- NCT00259285
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Surgical Site Infection, Pancreatic Neoplasms
Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections
Pancreaticoduodenectomy is associated with high perioperative morbidity, with surgical site infection (SSIs) being one of the most common complications.
- Conditions
- Surgical Site Infection, Pancreatic Neoplasms, Pancreatic Cancer, Chemotherapy Effects
- Trial name
- NCT03021668
- Testing
- Prevena Peel & Place Dressing, Standard Closure of the Surgical Incision
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Johns Hopkins University
Breast Cancer, Triple Negative Breast Cancer
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients…
- Trial name
- NCT03750240
- Testing
- Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Breast Cancer
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer
To test whether the addition of the COX-2 inhibitor, celecoxib, will decrease the gene expression of CYP19 in breast cancers collected from postmenopausal women that receive neoadjuvant exemestane.
- Trial name
- NCT00201773
- Testing
- Exemestane, Celecoxib, Correlative studies
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ulcerative Colitis
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the efficacy of SHP647 in inducing remission, based on composite score of patient-reported symptoms and centrally read endoscopy, in participants with moderate to severe ulcerative colitis…
- Trial name
- FIGARO UC 302 (NCT03259308)
- Testing
- Ontamalimab
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 279 people
- Sponsor
- Shire
Breast Cancer, Breast Tumors
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
To determine the accuracy of NIR/US assessment of tumor vasculature and oxygen changes in predicting and monitoring early neoadjuvant treatment response compared to pathological response.
- Conditions
- Breast Cancer, Breast Tumors, Cancer of Breast, Cancer of the Breast
- Trial name
- NCT02891681
- Testing
- Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Washington University School of Medicine
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer
This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer.
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT03106077
- Testing
- Mirvetuximab Soravtansine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer (NSCLC)
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.
- Trial name
- NEOMUN (NCT03197467)
- Testing
- Pembrolizumab
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- AIO-Studien-gGmbH
Melanoma, Malignant Melanoma
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
- Conditions
- Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma
- Trial name
- NCT01321437
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, Axitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, Irvine
Breast Cancer
Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients
Treatment consists of 4 AC cycles followed by 2 weekly docetaxel cycles (12 infusions). The pathological complete response rate obtained in previous studies is around 12%.
- Trial name
- NCT00129376
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 6 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Spanish Breast Cancer Research Group
Colon Cancer, Rectal Cancer
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
The purpose of this study is to find out how well patients with cancer of the rectum do if they get all of their other treatment - chemotherapy by itself followed by chemotherapy and radiation together - before surgery.
- Trial name
- NCT01363843
- Testing
- FOLFOX6, RT with concurrent chemotherapy, Surgery
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- William Sikov MD
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
This pilot clinical trial studies the side effects and how well cetuximab before surgery works in treating patients with skin cancer that forms, grows, and spreads quickly and has spread from where it started to nearby tissue or…
- Trial name
- NCT02324608
- Testing
- cetuximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rutgers, The State University of New Jersey
Bladder Cancer
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer (MIBC) who can not receive cisplatin or refuse cisplatin therapy will receive nivolumab or nivolumab/lirilumab before a planned surgical procedure called a radical cystectomy (RC) to…
- Trial name
- PrE0807 (NCT03532451)
- Testing
- Nivolumab, Nivolumab/Lirilumab
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- PrECOG, LLC.
Histoplasmosis, AIDS
Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients
Disseminated histoplasmosis (DH) is one of the major AIDS-defining infections responsible for high mortality rates in HIV-infected patients.
- Trial name
- NCT04059770
- Testing
- single dose of L-AmB, 2 doses of L-AmB, 2 weeks of L-AmB
- Where
- Brazil
- Volunteers
- 118 people
- Sponsor
- Alessandro Pasqualotto
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
This partially randomized phase I/II trial studies the side effects and best dose of elotuzumab and to see how well it works when given together with lenalidomide, bortezomib, and dexamethasone in treating patients with newly…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
- Trial name
- NCT01668719
- Testing
- Bortezomib, Dexamethasone, Elotuzumab
- Where
- 417 sites in United States
- Volunteers
- 142 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery.
- Trial name
- NCT02520063
- Testing
- Letrozole, Everolimus, TRC105
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
This single arm study will assess the efficacy and safety of combination first-line treatment with docetaxel + Xeloda + Avastin in patients with inflammatory or locally advanced breast cancer.
- Trial name
- NCT00576901
- Testing
- bevacizumab [Avastin], Docetaxel, Xeloda
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
The purpose of this study is to see whether adding everolimus to hormone treatment before breast surgery will increase the chances of shrinking the breast cancer in those patients with hormone-responsive breast cancer and a lower…
- Trial name
- NCT02236572
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University